Welcome to our dedicated page for Korro Bio news (Ticker: KRRO), a resource for investors and traders seeking the latest updates and insights on Korro Bio stock.
Korro Bio, Inc. develops genetic medicines based on RNA editing for rare and highly prevalent diseases. The company uses its OPERA® oligonucleotide promoted editing of RNA platform to design therapies that harness endogenous RNA editing for precise, transient single-base edits.
Korro Bio news commonly covers corporate updates, financial results, scientific presentations, investor conference activity, and pipeline progress. Recurring program topics include KRRO-121 for hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research for alpha-1 antitrypsin deficiency, private placement financings, equity-inducement grants, and other capital-structure and governance updates.
Korro Bio (Nasdaq: KRRO) selected KRRO-111 as a development candidate for the potential treatment of alpha-1 antitrypsin deficiency (AATD), a genetic liver and lung disorder. KRRO-111 is a subcutaneous GalNAc-conjugated oligonucleotide designed to repair the pathogenic SERPINA1 SNV via RNA editing.
In preclinical PiZZ mouse studies, KRRO-111 achieved >90% editing of AAT transcripts, ~90% functional M-AAT protein in plasma, ~95% reduction in non-inclusion Z-AAT at days 28 and 56, and ~69% reduction of inclusion-associated Z-AAT at day 28, suggesting potential improvement in both liver and lung manifestations.
Korro Bio (Nasdaq: KRRO) granted a non-statutory stock option as an inducement award to one newly hired employee under its 2026 Inducement Plan, in line with Nasdaq Listing Rule 5635(c)(4).
The option covers 3,000 shares at an exercise price of $11.20 per share, has a ten-year term, and vests over four years based on continued service.
Korro (Nasdaq: KRRO) reported Q1 2026 results and a corporate update on May 7, 2026. Cash and marketable securities totaled $157.1M as of March 31, 2026, after an oversubscribed $85M private placement. Lead program KRRO-121 targets hyperammonemia with a regulatory filing expected in H2 2026. A GalNAc AATD program achieved >90% in vivo RNA editing; a development candidate is expected in Q2 2026. Company expects cash runway into H2 2028 and will present multiple data sets at ASGCT 2026.
Korro (Nasdaq: KRRO) announced executives will participate in two investor conferences in May 2026. Presenters include Ram Aiyar (CEO & President), Jeffrey Cerio (SVP & General Counsel), Todd Chappell (COO) and Loïc Vincent (CSO).
Events: HCW BioConnect Nasdaq Investor Conference on May 19, 2026 at 4:00 PM ET (fireside chat), and RBC Capital Markets Global Healthcare Conference on May 20, 2026 at 11:30 AM ET (fireside chat).
Korro Bio (Nasdaq: KRRO) announced multiple oral and poster presentations at scientific conferences in April–May 2026 highlighting data from its OPERA® oligonucleotide RNA editing platform. Presentations cover preclinical hyperammonemia models, AATD RNA editing, ALS TDP-43 biology, platform chemistry, and healthcare utilization in hepatic encephalopathy.
Korro Bio (Nasdaq: KRRO) announced an inducement grant under Nasdaq Listing Rule 5635(c)(4) for a newly hired employee.
Korro granted a nonstatutory stock option to purchase 15,000 shares at an exercise price of $13.46 per share (closing price on April 8, 2026). The option has a 10-year term and vests over four years (25% at year one, then monthly over 36 months). The grant was approved by a majority of independent directors under Korro's 2026 Inducement Plan and was made as an inducement to hire in accordance with Nasdaq rule 5635(c)(4).
Korro (Nasdaq: KRRO) nominated KRRO-121 for clinical development to treat hyperammonemia in UCDs and hepatic encephalopathy and advanced a GalNAc AATD program with >90% in vivo RNA editing.
The company closed an oversubscribed $85M private placement and expects cash runway into H2 2028; full‑year 2025 net loss was $117.3M.
Korro (Nasdaq: KRRO) announced an oversubscribed private placement expected to raise approximately $85 million in gross proceeds, led by Venrock Healthcare Capital Partners on March 9, 2026. The financing comprises 4,501,928 common shares at $11.11 and pre-funded warrants for 3,148,836 shares.
Proceeds, together with unaudited cash, cash equivalents and marketable securities of $85.2 million as of December 31, 2025, are expected to extend Korro’s cash runway into the second half of 2028 and fund clinical data and development for KRRO-121, an AATD GalNAc program, and other pipeline programs.
Korro (Nasdaq: KRRO) said CEO Ram Aiyar, Ph.D., will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 3, 2026, at 11:10 a.m. ET. The event runs March 2–4, 2026, at the Boston Marriott Copley Place.
Korro (Nasdaq: KRRO) will host a virtual Analyst Day on Jan 27, 2026, 8–10 a.m. ET with management, hepatologist Bruce Scharschmidt, MD, and caregiver Michelle Dinon. Presentations will cover the unmet need in hyperammonemia, limitations of current treatments, and Korro’s development of KRRO-121, a GalNAc-conjugated construct intended to activate a biological pathway via RNA editing. The company will share preclinical data that support an anticipated regulatory filing for a first-in-human trial in H2 2026. Updates also note a GalNAc AATD program achieving >90% in vivo RNA editing and a development candidate nomination expected in H1 2026. A replay will be available for 30 days on the company website.